Wilmington, DE – According to filings with the U.S. Securities and Exchange Commission, NiKang Therapeutics is raising $199,999,915.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Zhenhai Gao played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About NiKang Therapeutics
NiKang Therapeutics is a early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Our target selection is driven by deep insights into disease biology and molecular pathways. Our discovery approach is informed by target structure biology and capitalizes on structure-based drug design. The successful implementation of our strategy enables us to rapidly and efficiently discover and advance proprietary drug candidates with the most desirable pharmacological features into clinical studies. We strive to bring transformative medicines to patients in need.

To learn more about NiKang Therapeutics, visit http://www.nikangtx.com/

Contact:
Zhenhai Gao, President and Chief Executive Officer
302-644-5450
zhenhai.gao@nikangtx.com
https://www.linkedin.com/in/zhenhai-gao-6834671/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved